Navigation Links
Genedata Phylosopher Selected for ERA-NET sncRNA Project
Date:6/1/2010

Genedata Phylosopher® is Central Management Solution for European Consortium Using Systems Biology to Study Infectious Diseases

(PRWEB) June 1, 2010 -- Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it has been selected to participate in an ERA-Net-funded applied pathogenomics project, which is using systems biology to identify the role of small non-coding RNA (sncRNA) in infectious diseases. The sncRNAomics European Research Consortium is identifying novel targets for diagnostics and therapy of five major high-risk gram-positive human microbial pathogens. The Genedata Phylosopher biological data management solution was chosen as the central management and infrastructure platform for sharing and interpreting the experimental data, in particular the next-generation sequencing and tiling array data generated within the consortium.

“We chose to partner with Genedata because they have a successful track record in transcriptome-based biomarker identification and also because they have the strongest product portfolio for centralized data management for target validation,” explained Dr. Torsten Hain of the University of Giessen (Germany) and sncRNAomics Project Coordinator. “In health care, and especially in a clinical environment, microbial resistance increases exponentially. Antibiotics have become a blunt sword and we need new approaches in diagnostics and therapy,” continued Dr. Hain. “Small non-coding RNAs in bacteria are an emerging class of new gene expression regulators, but their role in colonization and pathogenicity is largely unknown. Within this interdisciplinary project we are applying for the first time a systems biology approach on major human pathogens to elucidate the role of sncRNAs, and to identify and validate new sncRNA-based diagnostic biomarkers and drug targets.”

Genedata Phylosopher will integrate all experimental data from the pathogens and the host organisms. Using a genome-wide scale and regulatory network approach, the consortium will adapt high-throughput technologies such as transcriptomics by tiling arrays as well as next-generation sequencing technologies to identify novel sncRNAs and to investigate their role in regulation. Genedata Phylosopher supports the reconstruction of disease pathways, in particular the refinement of functional assignment of genes, transcripts, proteins, regulatory motifs, RNAs and their molecular interactions, to regulatory networks during host-pathogen interactions.

"We are delighted to have this international and interdisciplinary consortium choose Genedata as their central data management and analysis infrastructure,” said Dr. Othmar Pfannes, CEO of Genedata. “This partnership further demonstrates Genedata’s leadership in delivering scalable and flexible research IT infrastructure solutions for target validation, drug development, and biomarker discovery, even for novel target classes such as sncRNAs.”

About sncRNAomics European Research Consortium
Novel anti-infectives are of high priority for global health care and sncRNAs in bacteria are an emerging class of new gene expression regulators, but their role in colonization and pathogenicity in largely unknown. The consortium brings together seven research groups from three countries to combine novel high-throughput sncRNA screening methods, whole-genome transcriptomics and proteomics and bioinformatics. These methods will be coupled with molecular characterization to provide new data regarding sncRNAs in major high-risk Grampositive microbes (e.g. Staphylococcus, Streptococcus, Enterococcus, Clostridium, and Listeria). Potential new drugs and diagnostic biomarkers will be validated using tissue culture and subsequently in in-vivo models. The sncRNAomics project is granted under the frame of the second multinational ERA-Net PathoGenoMics call. For more information, please visit www.pathogenomics-era.net/2ndJointCall.

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, and Genedata Analyst™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany and the US. www.genedata.com.

###

Read the full story at http://www.prweb.com/releases/2010/06/prweb4072014.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Expressionist 6 with New Refiner MS Capabilities Debuts at 58th ASMS Conference on Mass Spectrometry
2. German MedSys Project Adopts Genedata Phylosopher for Research Informatics
3. Genedata Screener 8 Advancing Analysis of HCS, HTS and Time Series Data Debuts at SBS 16th Annual Conference
4. Genedata Announces Five-Year Agreement Extension with Kluyver Centre for Genomics of Industrial Fermentation
5. Bringing Statistics to Biologists - New Genedata Analyst Launches at Society of Toxicology 49th Annual Meeting
6. Evonik Extends Long-term Research & Development Partnership with Genedata
7. RIKEN Center for Genomics Medicine Chooses Genedata Expressionist for High Throughput Proteomics R&D
8. Genedata at HCA Announces Banner Year for Genedata Screener at Leading Pharmaceutical Companies
9. MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products
10. Genedata and the Institute of Experimental Medicine, Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project
11. Genedata Screener Supports Small Molecule Research at the Broad Institute of Harvard and MIT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received a ... a patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit research ... at The Scripps Research Institute in San Diego, CA. , The aim ...
(Date:4/28/2016)... YORK , April 28, 2016 ... acceleration company reports the Company,s CEO  was featured ... titled Accelerators Enter When VCs Fear To Tread: ... Science Leader magazine is an essential ... for everything from emerging biotechs to Big Pharmas. ...
(Date:4/28/2016)... ... April 28, 2016 , ... Morris Midwest ( http://www.morrismidwest.com ), ... manufacturers at its Maple Grove, Minnesota technical center, May 11-12. The event ... Almost 20 leading suppliers of tooling, accessories, software and other related technology ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... Touch screen mobile devices with fingerprint recognition for secure access, voice recognition for ... a few ways consumers are interacting with biometrics technology today. But if ...
Breaking Biology Technology:
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
Breaking Biology News(10 mins):